Cargando…

Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study

Detalles Bibliográficos
Autores principales:	Courcelle, Romain, Gaudry, Stéphane, Serck, Nicolas, Blonz, Gauthier, Lascarrou, Jean-Baptiste, Grimaldi, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369441/ https://www.ncbi.nlm.nih.gov/pubmed/32684169 http://dx.doi.org/10.1186/s13054-020-03164-2

Ejemplares similares

Factors Associated With Pulmonary Embolism Among Coronavirus Disease 2019 Acute Respiratory Distress Syndrome: A Multicenter Study Among 375 Patients
por: Soumagne, Thibaud, et al.
Publicado: (2020)

Static compliance of the respiratory system in COVID-19 related ARDS: an international multicenter study
por: Vandenbunder, Benoit, et al.
Publicado: (2021)

Barotrauma in COVID-19 acute respiratory distress syndrome: retrospective analysis of the COVADIS prospective multicenter observational database
por: Serck, Nicolas, et al.
Publicado: (2023)

Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study
por: Lascarrou, Jean-Baptiste, et al.
Publicado: (2021)

Correction: Barotrauma in COVID-19 acute respiratory distress syndrome: retrospective analysis of the COVADIS prospective multicenter observational database
por: Serck, Nicolas, et al.
Publicado: (2023)

Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study
por: Grimaldi, David, et al.
Publicado: (2020)

Neuromuscular blocking agents for acute respiratory distress syndrome
por: Torbic, Heather, et al.
Publicado: (2019)

Is it appropriate for acute respiratory distress syndrome patients with neuromuscular blocking agents?
por: Tan, Zhimin, et al.
Publicado: (2023)

Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region
por: Blonz, Gauthier, et al.
Publicado: (2021)

Neuromuscular blocking agents for acute respiratory distress syndrome: how did we get conflicting results?
por: Torbic, Heather, et al.
Publicado: (2019)

Neuromuscular blocking agents for acute respiratory distress syndrome: an updated meta-analysis of randomized controlled trials
por: Zheng, Zhongjun, et al.
Publicado: (2020)

Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials
por: Tarazan, Nehal, et al.
Publicado: (2020)

Role of Neuromuscular Blocking Agents in Acute Respiratory Distress Syndrome: An Updated Meta-Analysis of Randomized Controlled Trials
por: Wei, Xue-biao, et al.
Publicado: (2020)

Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials
por: Chang, Wei, et al.
Publicado: (2020)

Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials
por: Alhazzani, Waleed, et al.
Publicado: (2013)

The Implementation of Protocol-Based Utilization of Neuromuscular Blocking Agent Using Clinical Variables in Acute Respiratory Distress Syndrome Patients
por: Hadique, Sarah, et al.
Publicado: (2021)

Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression
por: Shao, Shuai, et al.
Publicado: (2020)

Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials
por: Pereira, VGM
Publicado: (2013)

Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials
por: Neto, Ary Serpa, et al.
Publicado: (2012)

Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents
por: Higashi, Michiko, et al.
Publicado: (2019)

Flexible organic frameworks sequester neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo
por: Wu, Yan, et al.
Publicado: (2022)

Neuromuscular blocking agents in the intensive care unit
por: Rodríguez-Blanco, Jonathan, et al.
Publicado: (2022)

Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
por: Raymond, Matthieu, et al.
Publicado: (2022)

Early Corticosteroid Therapy May Increase Ventilator-Associated Lower Respiratory Tract Infection in Critically Ill Patients with COVID-19: A Multicenter Retrospective Cohort Study
por: Mesland, Jean-Baptiste, et al.
Publicado: (2022)

Tracheal Intubation Without the Use of Neuromuscular Blocking Agents
por: Prakash, Smita
Publicado: (2012)

Urgent intubation without neuromuscular blocking agents and the risk of tracheostomy
por: Fujinaga, Jun, et al.
Publicado: (2019)

The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents
por: Honore, Patrick M., et al.
Publicado: (2020)

Neuromuscular blockers in the acute respiratory distress syndrome: A meta-analysis
por: Hua, Yusi, et al.
Publicado: (2020)

Impact of late administration of corticosteroids in COVID-19 ARDS
por: Mongardon, Nicolas, et al.
Publicado: (2020)

Sugammadex as a reversal agent for neuromuscular block: an evidence-based review
por: Schaller, Stefan Josef, et al.
Publicado: (2013)

Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents
por: Kim, Yong Byum, et al.
Publicado: (2017)

Potential cross-allergic reaction from pholcodine and neuromuscular blocking agents
Publicado: (2022)

Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications
por: Cho, Sung-Ae, et al.
Publicado: (2022)

Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents
por: ÖZBEY, Nazlı Bahar, et al.
Publicado: (2022)

Reversal of neuromuscular block
por: Bhalotra, Anju Romina
Publicado: (2018)

Predictors of negative first SARS-CoV-2 RT-PCR despite final diagnosis of COVID-19 and association with outcome
por: Lascarrou, Jean-Baptiste, et al.
Publicado: (2021)

Threshold for basophil activation test positivity in neuromuscular blocking agents hypersensitivity reactions
por: Hagau, Natalia, et al.
Publicado: (2013)

Endotracheal Intubation Without Neuromuscular Blocking Agents: Is It a Good and Safe Option?
por: Akan, Mert, et al.
Publicado: (2012)

Erratum: Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents
por: Kim, Yong Beom, et al.
Publicado: (2017)

Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey
por: Kim, Jin Sun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f8t79ihrrpk1j6k5aitsjfrrsb